- Home
- OSCR vs PRAX Comparison
OSCR vs PRAX Comparison
Compare OSCR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSCR | PRAX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OSCR | PRAX |
|---|---|---|
| Price | $31.43 | $319.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $16.88 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 6.7M | 564.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $11,701,427,000.00 | N/A |
| Revenue This Year | $63.89 | N/A |
| Revenue Next Year | $5.30 | $7,758.26 |
| P/E Ratio | $15.43 | ★ N/A |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $10.69 | $37.25 |
| 52 Week High | $33.10 | $366.52 |
Technical Indicators
Market Signals| Indicator | OSCR | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 66.71 | 54.70 |
| Support Level | $12.01 | $308.40 |
| Resistance Level | N/A | $327.65 |
| Average True Range (ATR) | 1.70 | 19.38 |
| MACD | 0.03 | 5.53 |
| Stochastic Oscillator | 69.28 | 65.58 |
Price Performance
Historical ComparisonAbout OSCR Oscar Health Inc.
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.